Literature DB >> 7911290

Foscarnet for suppression of human immunodeficiency virus replication.

C V Fletcher1, A C Collier, F S Rhame, D Bennett, M F Para, C C Beatty, C E Jones, H H Balfour.   

Abstract

The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7911290      PMCID： PMC284505          DOI： 10.1128/AAC.38.3.604

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

2.  Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.

Authors:  M A Jacobson; S Crowe; J Levy; F Aweeka; J Gambertoglio; N McManus; J Mills
Journal:  J Infect Dis       Date:  1988-10       Impact factor: 5.226

3.  Simulation of linear compartment models with application to nuclear medicine kinetic modeling.

Authors:  D Z D'Argenio; A Schumitzky; W Wolf
Journal:  Comput Methods Programs Biomed       Date:  1988 Jul-Aug       Impact factor: 5.428

4.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

5.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

6.  Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.

Authors:  J Sjövall; A Karlsson; S Ogenstad; E Sandström; M Saarimäki
Journal:  Clin Pharmacol Ther       Date:  1988-07       Impact factor: 6.875

Review 7.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

8.  Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.

Authors:  F Aweeka; J Gambertoglio; J Mills; M A Jacobson
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

9.  Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.

Authors:  J Sjövall; S Bergdahl; G Movin; S Ogenstad; M Saarimäki
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

10.  Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).

Authors:  F T Aweeka; J G Gambertoglio; C van der Horst; R Raasch; M A Jacobson
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191
View more
  10 in total

1.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

Authors:  S Palmer; J Harmenberg; S Cox
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

Review 3.  Treatment of HIV infection. Tolerability of commonly used antiretroviral agents.

Authors:  D W Notermans; R van Leeuwen; J M Lange
Journal:  Drug Saf       Date:  1996-09       Impact factor: 5.606

4.  Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.

Authors:  H H Balfour; C V Fletcher; A Erice; W K Henry; E P Acosta; S A Smith; M A Holm; G Boivin; D H Shepp; C S Crumpacker; C A Eaton; S S Martin-Munley
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

Authors:  J W Mellors; H Z Bazmi; R F Schinazi; B M Roy; Y Hsiou; E Arnold; J Weir; D L Mayers
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

6.  Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

Authors:  G Tachedjian; M French; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  Foscarnet alters antidiuretic hormone-mediated transport.

Authors:  B S Hoch; S J Shahmehdi; B M Louis; H I Lipner
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

8.  Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.

Authors:  R F Omar; N Dusserre; A Désormeaux; L Poulin; M Tremblay; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 9.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

Review 10.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.